Androgen deprivation therapy (castration therapy) and pedophilia: What's new

被引:2
|
作者
Silvani, Mauro [1 ]
Mondaini, Nicola
Zucchi, Alessandro
机构
[1] Infermi Hosp, Urol Dept, Biella, Italy
关键词
Pedophilia; Chemical castration; Andrology;
D O I
10.4081/aiua.2015.3.222
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Andrology is a constantly evolving discipline, embracing social problems like pedophilia and its pharmacological treatment. With regard to chemical castration, the andrologist may perform an important role as part of a team of specialists. At present, no knowledge is available regarding hormonal, chromosomal or genetic alterations involved in pedophilia. International legislation primarily aims to defend childhood, but does not provide for compulsory treatment. We reviewed international literature that, at present, only comprises a few reports on research concerning androgen deprivation. Most of these refer to the use of leuprolide acetate, rather than medroxyprogesterone and cyproterone acetate, which present a larger number of side effects. Current opinions on chemical castration for pedophilia are discordant. Some surveys confirm that therapy reduces sexual thoughts and fantasies, especially in recidivism. On the other hand, some authors report that chemical castration does not modify the pedophile's personality. In our opinion, once existing legislation has changed, andrologists could play a significant role in the selection of patients to receive androgen deprivation therapy, due in part to their knowledge about its action and side effects.
引用
收藏
页码:222 / 226
页数:5
相关论文
共 50 条
  • [31] Androgen deprivation therapy and cardiovascular disease
    Melloni, Chiara
    Roe, Matthew T.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (02) : 45 - 52
  • [33] Optimizing the duration of androgen deprivation therapy
    Eric M. Horwitz
    [J]. Nature Reviews Urology, 2009, 6 : 527 - 529
  • [34] CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
    Boban, Marko
    [J]. ACTA CLINICA CROATICA, 2019, 58 (01) : 60 - 63
  • [35] Androgen deprivation therapy and BMD loss
    Katherine Sole
    [J]. Nature Clinical Practice Oncology, 2006, 3 (3): : 123 - 123
  • [36] Androgen deprivation therapy for prostate cancer
    Das, Manjulika
    [J]. LANCET ONCOLOGY, 2017, 18 (10): : E567 - E567
  • [37] Androgen deprivation therapy and cardiovascular complications
    Poljak, Z.
    Hulin, I
    Maruscakova, L.
    Carter, A.
    Mladosievicova, B.
    [J]. BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2016, 117 (10): : 557 - 561
  • [38] Cardiovascular Toxicity of Androgen Deprivation Therapy
    Julia Boland
    William Choi
    Maximillian Lee
    Jianqing Lin
    [J]. Current Cardiology Reports, 2021, 23
  • [39] QOL FOR INTERMITTENT ANDROGEN DEPRIVATION THERAPY
    Berry, D.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 25 - 25
  • [40] Cardiovascular Toxicities of Androgen Deprivation Therapy
    Challa, Azariyas A.
    Calaway, Adam Christopher
    Cullen, Jennifer
    Garcia, Jorge
    Desai, Nihar
    Weintraub, Neal L.
    Deswal, Anita
    Kutty, Shelby
    Vallakati, Ajay
    Addison, Daniel
    Baliga, Ragavendra
    Campbell, Courtney M.
    Guha, Avirup
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (06)